Tekmira Says USPTO Declares Interference for Alnylam Patent as Firms Continue Litigation | GenomeWeb

Tekmira Pharmaceuticals this week announced that the US Patent and Trademark Office has declared a patent interference for Alnylam Pharmaceuticals' US patent covering siRNAs against a key target for its phase I liver cancer drug ALN-VSP.

As part of an ongoing lawsuit between the companies, Tekmira has alleged that certain claims in the patent, No. 7,718,629, are invalid in light of a Tekmira patent application. The patent office will now determine the priority of the subject matter in Alnylam's patent with respect to Tekmira's intellectual property, it said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.